Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003386 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00003386 is a Phase 2 study that was terminated before completion, run by Gynecologic Oncology Group.
The verdict
NCT00003386, a Phase 2 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.
Interventions
- DRUG cisplatin
- DRUG carboplatin
- DRUG cyclophosphamide
- BIOLOGICAL autologous tumor cell vaccine
- BIOLOGICAL BCG vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003386
The ClinicalTrials.gov registry entry for NCT00003386 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00003386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003386 about?
NCT00003386 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer". RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.
What is the current status of trial NCT00003386?
This trial is currently terminated. It is a Phase 2 study. The study started on 1999-07.
What interventions are being tested in trial NCT00003386?
The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), cyclophosphamide (DRUG), autologous tumor cell vaccine (BIOLOGICAL), BCG vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003386?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.